-
Press Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
-
Press Release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
-
Press Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
-
Press Release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
-
Press Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Press Release
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
-
Press Release
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
-
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)